NCT05710198
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
At risk: Primary completion moved 3 years 3 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Jul 1, 2029 Show 6 more changesShow less
- Eligibility criteria expanded, about 19 words
- Enrollment closed, study ongoing
- Final enrollment: 873 participants (planned 1000)
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Apr 1, 2023 to Dec 11, 2023
- Minor Study description shortened, about 1,007 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Citicoline eye drops 2%. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication.
Placebo eye drops. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication
Drugs: Citicoline eye drops 2%, Placebo
Sites
1 site in 1 country
- Presidio Ospedale San PaoloMilan, MI, Italy